

Metastasis-Free Survival (MFS)

Metastasis-Free Survival (MFS) is a clinical trial endpoint that measures the length of time from the start of treatment (or randomization) until the development of **distant metastatic disease** or **death from any cause**, whichever occurs first.

Definition

- MFS = Time from treatment initiation to:
 - First occurrence of **distant metastasis** (confirmed radiologically or pathologically), or
 - **Death from any cause**

Context of Use

- Commonly used in:
 - **Prostate cancer** (especially non-metastatic castration-resistant prostate cancer, nmCRPC)
 - Other solid tumors where **distant spread** is the key determinant of prognosis
- Serves as a **surrogate endpoint** for overall survival in certain trials.

Advantages

- Focuses on clinically meaningful progression (distant metastasis).
- Can provide **earlier readouts** than overall survival (OS).
- Useful in settings with long survival times but high risk of distant spread.

Limitations

- May not capture **local progression**.
- Imaging frequency and sensitivity may affect detection.
- Not always validated as a **true surrogate** for OS in all cancers.

Related Terms

- [Progression-Free Survival \(PFS\)](#)
- [Overall Survival \(OS\)](#)
- [Disease-Free Survival \(DFS\)](#)
- [Distant Metastasis](#)

Last
update: 2025/07/03 06:39 metastasis-free_survival https://neurosurgerywiki.com/wiki/doku.php?id=metastasis%E2%80%91free_survival&rev=1751524795

From:
<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:
https://neurosurgerywiki.com/wiki/doku.php?id=metastasis%E2%80%91free_survival&rev=1751524795

Last update: **2025/07/03 06:39**

